Novo Nordisk gets another FDA warning over GLP-1 ad claims
2026-03-04 08:23:24 ET
More on Novo Nordisk A/S
- Pricing Pressure And Panic: What The Market May Be Missing In Novo Nordisk
- Eli Lilly Vs. Novo Nordisk: The Valuation Gap Is Unreasonable
- Why I'm Still Bullish On Novo Nordisk Despite Recent Setbacks
- Novo’s China obesity drug posts positive mid-stage trial results
- Novo Nordisk board proposes DKK 7.95 final dividend for 2025, initiates DKK 15B buyback
Read the full article on Seeking Alpha
For further details see:
Novo Nordisk gets another FDA warning over GLP-1 ad claimsNASDAQ: NONOF
NONOF Trading
1.93% G/L:
$38.755 Last:
48,985 Volume:
$37.4975 Open:



